



#### Co-funded by the European Union

# InnoStars SPICE Programme – Call for SPICE Implementing Partners

EIT Health e.V.

Version 1.0 22 January 2025



# History of changes

Version	Publication date	Changes
1.0	22 January 2025	Initial version

Any changes to this call are listed in the table above. Amended copies of the call will be available on the call website.

## Contents

1	Call summary1		
2	Background1		1
3	Scope.		2
	3.1	Objectives	2
	3.2	Activities	3
	3.3	Duration of activities	5
	3.4	Available budget, form of funding and payment schedule	5
	3.5	Timeline	6
4	Call co	nditions	6
	4.1	Admissibility	6
	4.2	Eligibility	7
	4.2.1	Entities eligible to participate	7
	4.2.2	RIS Community	7
	4.2.3	Eligible activities	7
	4.2.4	Eligible costs	8
	4.3	Specific eligibility conditions	8
	4.4	Exclusion	8
5	Evalua	tion and Selection	9
	5.1	Submission	9
	5.2	Award criteria and scoring	9
	5.3	Procedure1	0
	5.4	Grounds for appeal and appeal procedure1	0
	5.5	Legal and financial set-up of the Grant Agreements1	1
6	Confid	entiality and conflict of interest1	1
7	Intellectual Property Rights rules		2
8	Communication and dissemination		2
9	Right t	o ex-post monitoring1	3
ANI	ANNEX 114		
ANI	ANNEX 215		





# 1 Call summary

MAIN FEATURES		
	EIT Health InnoStars initiates a new program, the Strategic Partnership Initiatives for Competitive Edge (SPICE) to jointly develop and market	
Why should you apply	innovative healthcare solutions. To implement the programme, we are looking for contributing partners to jointly accelerate the selected SPICE Subgrantees and their innovative healthcare solutions.	
Who can apply	This Call is open to all legal entities such as business organisations, academic, research and healthcare institutions from eligible RIS countries and territories	
Key dates	Call opening: 22.01.2025 Call closure: 21.03.2025 Communication of results: 26.03 .2025 Start of the eligibility of provided services: 01.03.2025 End of the eligibility of provided services: 31.12.2025	
Budget and maximum funding	The indicative EIT funding available for the grants under this call is up to EUR 1.000.000. The actual funding amount of a single SPICE Implementing Partner depends on the services selected by the SPICE beneficiaries. The total funding for a single SPICE Implementing partners may not exceed EUR 250,000.	
Link to the submission portal	EIT Health Application platform	
Documents to be submitted	<ul> <li>Application form</li> <li>Detailed description of the service (Service plan) (included in the Application form)</li> </ul>	
Contact details	alessio.smeraldo@eithealth.eu	

## 2 Background

The European Institute of Innovation and Technology (EIT) is Europe's largest innovation ecosystem bringing together close to 2,400 partners from top business, research and education organisations across Europe in over 50 innovation hubs. The EIT strengthens Europe's ability to innovate by powering solutions to pressing global challenges and by nurturing entrepreneurial talent to create sustainable growth and skilled jobs in Europe. The EIT is an EU body and an integral part of Horizon Europe, the EU Framework Programme for Research and Innovation. The Institute supports dynamic pan-European partnerships, EIT Knowledge and Innovation Communities, composed of leading companies, research labs and universities each dedicated to solving a pressing global challenge, from climate change to health, to renewable energy. For more information visit <a href="https://eit.europa.eu/">https://eit.europa.eu/</a>

<u>EIT Health</u> is a network of best-in-class health innovators supported by the European Institute of Innovation and Technology (EIT), a body of the European Union. We collaborate across borders to deliver new solutions enabling European citizens to live longer, healthier lives. As Europeans tackle the





challenge of increasing chronic diseases and multi-morbidity and seek to realise the opportunities that technology offers to move beyond conventional approaches to treatment, prevention and healthy lifestyles, we need thought leaders, innovators and efficient ways to bring innovative healthcare solutions to market. EIT Health addresses these needs. We connect all relevant healthcare players across European borders – making sure to include all sides of the "knowledge triangle" so that innovation can happen at the intersection of research, education and business for the benefit of citizens. For more information visit: www.eithealth.eu.

<u>EIT Health InnoStars</u> is one of the eight geographical areas of EIT Health. It covers half of Europe, including Poland, Hungary, Italy, and Portugal, as well as additional regions included in the EIT Regional Innovation Scheme. This is a group of countries qualified by the European Innovation Scoreboard (EIS) as moderate innovators. InnoStars is focused on promoting entrepreneurship, innovation and education in the domain of healthcare, healthy living and active ageing in the region and closing the gap between regions that are leaders in innovation and those regions which are progressing.

The <u>EIT Regional Innovation Scheme</u> (EIT RIS) was created by the European Institute of Innovation and Technology (EIT) to close the gap between regions that are leaders in innovation and those regions that are progressing. It aims to incubate the regions in Central, Eastern and Southern Europe, discovering their unique innovation assets and engaging local innovators to participate in pan-European programmes. In the field of healthcare, the programme has been developing since 2016, and it is coordinated by EIT Health InnoStars. The list of the eligible RIS countries can be found at <u>https://eit.europa.eu/activities/eit-regional-innovation-scheme-ris-closing-innovation-divide-europe</u>

### 3 Scope

#### 3.1 Objectives

The Strategic Partnership Initiatives for Competitive Edge (SPICE) program is a new activity of EIT Health InnoStars (InnoStars) that attracts, selects and supports organizations from EIT RIS countries in the joint development and commercialization of their innovative solutions in the health sector. InnoStars wishes to enter into a commercial agreement with the subgrantees of SPICE program and obtain income - such as margin, license fee, success fee, royalties, distribution fees, etc – post-project through a contractual relationship.

Approximately 10 subgrantees will be funded in the SPICE program to further develop their innovative solutions. The selected SPICE subgrantees and their innovative solutions will undergo a due diligence process, during which necessary services to support the development and commercialization of their innovative solution will be identified. These support services will be provided by EIT Health InnoStars and SPICE Implementing Partners selected in this call as part of SPICE activity. As a first step, SPICE Implementing Partners selected in this call will be included in a long list. The SPICE beneficiaries can select the SPICE Implementing Partner based on their needs. Therefore, selection during this call does not constitute an automatic service order or funding. The SPICE Implementing Partners selected by subgrantees, their service activities and their budgets will be funded within the '230101 RIS Engage Local Players' Project Grant Agreement (PGA).





EIT Health is looking for legal entities from the eligible RIS countries who are willing to become SPICE Implementing Partners.

#### 3.2 Activities

Please note that since the activities of the SPICE program will be new activities, even EIT Health Partners already included in the PGA must apply to become SPICE Implementing Partners and to have their new activity and/or budget eligible.

Selected SPICE Implementing Partners will provide customized services to the subgrantees of the SPICE program in the following 10 service areas:

SERVICES	SUB-SERVICES	BRIEF DESCRIPTION
1. Regulatory Support	Regulatory Consulting	Guidance on navigating the regulatory landscape (IP, CE mark, FDA, EMA and other international regulatory bodies)
	Compliance Audits	Conducting audits to ensure that the company meets all relevant regulatory requirements.
	Documentation Support	Assistance with preparing and managing regulatory documentation and submissions.
2. Technology and Innovation support	Product Development and Improvement	Support in product development, iterative improvements, and integrating new technologies.
	Technology Risk Management	Identifying and managing risks associated with technology implementations.
3. Data Privacy	Data Protection Regulations	Compliance with data protection laws such as GDPR.
	Cybersecurity	Development of cybersecurity policies and compliance with standards.
4. Clinical Validation	Clinical Trial Design and Management	Support in designing and managing clinical trials to validate the effectiveness and safety of their technology.
	Data Analysis and Interpretation	Providing expertise in analysing clinical trial data and translating it into actionable insights.
	Access to Hospital	Assessing technology effectiveness and integration in the hospital environment
	Access to Clinical Data	Facilitating the access to data banks/pool
	Access to Patients and Healthcare providers	Engaging final users to gather feedback and/or prove the effectiveness of the technology
5. Quality Assurance	Quality Management Systems (QMS)	Helping implement and maintain QMS compliant with standards





	Product Testing and	Assistance with product testing,	
	Certification	validation, and certification	
		processes.	
6. Business Strategy and	Market Analysis and Strategy	In-depth market analysis and	
Improvement		strategy development to identify	
		opportunities and optimize	
		market entry.	
	<b>Business Model Optimization</b>	Evaluating and improving the	
		current business model to	
		enhance scalability and	
		profitability.	
7. Financial Modelling	Budgeting and Forecasting	Creating detailed budgets to	
		manage costs and revenues,	
		forecasting future financial	
		performance based on historical	
		data and assumptions, break-	
		even and profit margin analysis	
	Scenario and Sensitivity Analysis	Exploring different business	
		scenarios (e.g., best case, worst	
		case) and how changes in key	
		assumptions impact financial	
		outcomes.	
	Business and Asset Valuation	Estimating the value of the	
		business/assets (technology,	
		machinery, intellectual property,	
		etc.) for sale, merger, or investment purposes.	
8. Commercialization Support	Go-to-Market Strategy	Developing a comprehensive go-	
8. commercialization Support	do-to-ivial ket Strategy	to-market strategy, including	
		pricing, distribution, and sales	
		channels.	
	Marketing and Branding	Assistance with marketing	
		strategies, brand development,	
		and digital marketing campaigns.	
9. Funding and Investment	Investment Advisory	Preparing companies to be	
		investor-ready providing	
		guidance on attracting and	
		managing investments	
10. Market scale-up and	Market Entry Strategy	Developing strategies for	
expansion		entering new geographical	
		markets, including regulatory,	
		cultural, and market dynamics.	

One partner can apply to a maximum of 2 services. The offered services will be evaluated separately.

Selected SPICE Implementing Partners are not eligible to receive funding from the underlying SPICE program. If a legal entity is selected in both SPICE calls for proposals, the partner must decide whether to continue as a SPICE subgrantee or implementing partner. The same legal entity cannot be a SPICE implementing partner and a SPICE subgrantee at the same time.

The total funding for a single SPICE Implementing partners may not exceed EUR 250,000.



## 3.3 Duration of activities

Starting date of eligibility of services: 01.03.2025

End date of eligibility of services: 31.12.2025

## 3.4 Available budget, form of funding and payment schedule

The indicative EIT funding available for the grants under this call is: up to EUR 1.000.000

The budget of each SPICE Implementing Partner selected by the SPICE subgrantees will be determined in the Business Plan annexed to the PGA based on the type and number of services required for the SPICE program subgrantees.

The form of grant is a budget-based actual cost action grant.

The selected SPICE Implementing Partners are entitled to up to 25% pre-financing. Selected entities are entitled to payments as follows:

PAYMENT TYPE	PAYMENT SCHEDULE
Pre-financing	The selected SPICE Implementing Partners will receive one kick-off payment from EIT Health upon completion of the following: - signing of the Internal Agreement; - signing of the FSA; - signing of this PGA; - completion of the Partner Profile in the Grant Management System;
Final payment	Following EIT approval of the 2025 cost report
(payment of balance)	(expected around September 2026)

#### 3.5 Foreseen outcomes, outputs and impact

# The EIT Health InnoStars SPICE Programme aims to contribute to the following EIT KPIs, with the assistance of the Implementing Partners selected through this call.

The Implementing Partners will work closely with SPICE subgrantees, providing critical support to help them reach the market and attract investments. While the KPIs are not achieved directly by the Implementing Partners, their contributions are vital in enabling the subgrantees to achieve these results:

#### a) EITHE02.2-EITRIS: EIT RIS Innovations launched on the market

- Number of innovations introduced to the market during the KAVA duration or within three years after its completion.
- Innovations include new or significantly improved products (goods or services) that are sold.
- Sub-KPI: Innovations introduced to the market during the call duration or within three years after completion with a recorded sales revenue of at least €10,000.



#### b) EITHE06.2-EITRIS: Investment attracted by KIC-supported EIT RIS start-ups and scale-ups

- Total amount (in EUR) of private and public capital attracted by supported start-ups or scaleups.
- Eligibility: Start-ups and scale-ups that have received KIC business creation services support or HEI CBI project support lasting at least two months, within a maximum of three years following the last received KIC KAVA project support activity.

#### 3.6 Timeline

If there are any changes to the dates, the participants will be notified well in advance by a change log that will be added to this document if relevant.

MILESTONE	DATES
Call opens	22.01.2025
Info session about the call	11.02.2025
Submission deadline	21.03.2025 at 03:59 PM (CET)
Evaluation	takes up to 60 days following the submission of application
Notification of applicants	maximum 90 days following the submission of application
Deadline for appeals	no later than 21 days after the error occurred

## 4 Call conditions

#### 4.1 Admissibility

Applications must be submitted before the deadline(s) indicated in Chapter 3.5.

Applications must be submitted electronically through the EIT Health Application platform

Applications must be submitted in English using the forms provided inside the electronic submission system. The structure and presentation must correspond to the instructions given in the forms.

Applications must be readable, accessible, and complete and contain all the requested information and mandatory annexes and supporting documents.

Submissions that are incomplete, late, or made through any other channel (for example, email or on paper) will not be accepted.

In addition to the above admissibility conditions, document, page, or section limits may be applied to parts of applications. The limits are clearly shown in the application templates in the electronic submission system. After the call deadline, part that exceed the limit and extra documents that are not specified as part of the application, will not be taken into consideration by the evaluators.





## 4.2 Eligibility

#### 4.2.1 Entities eligible to participate

This Call is open to all legal entities such as business organisations, academic, research and healthcare institutions.

Applicant shall:

- 1. be a legal entity registered in one of the following RIS eligible countries:
  - EU Member States: Bulgaria, Croatia, Cyprus, Czechia, Estonia, Greece, Hungary<sup>1</sup>, Italy, Latvia, Lithuania, Malta, Poland, Portugal, Romania, Slovakia, Slovenia, Spain.
  - Horizon Europe Associated Countries: Albania, Bosnia and Herzegovina, Israel, Montenegro, North Macedonia, Serbia, Türkiye, Ukraine.
  - Outermost Regions: Guadeloupe, French Guiana, Réunion, Martinique, Mayotte, and Saint-Martin (France), the Azores and Madeira (Portugal), and the Canary Islands (Spain)
- 2. have at least 5 years of experience in the service(s) they are applying to provide, and at least 3 years of experience in each sub-service that belongs to the given service

#### 4.2.2 RIS Community

The support of implementation of projects is a core activity of EIT Health InnoStars. Beyond this activity, the EIT Health community connects members and runs networking activities to design and plan strategic actions, to drive impact and accelerate systemic change, including accelerating market adoption of innovative solutions into everyday city operations.

As a first step, SPICE Implementing Partners selected in this call will be included in a long list. The SPICE beneficiaries can select SPICE Implementing Partners from the list based on their needs. Therefore, selection during the selection process of this call does not constitute an automatic service order or funding. The SPICE Implementing Partners selected by subgrantees, their service activities and their budgets will be funded by the '230101 RIS Engage Local Players' Project Grant Agreement (PGA).

#### 4.2.3 Eligible activities

Only actions that are directly related to the services described in Chapter 3.2 and provided to SPICE call participants are eligible.

<sup>&</sup>lt;sup>1</sup> Based on the Council Implementing Decision (EU) 2022/2506) on measures for the protection of the Union budget against breaches of the principles of the rule of law in Hungary, effective as of 16th December 2022, no legal commitments shall be entered into with any public interest trust established on the basis of the Hungarian Act IX of 2021 or any entity maintained by such a public interest trust. Please check also the related list of Frequently Asked Questions. It is progressively updated as soon as further guidance is available. You can find an indicative – \_non-exhaustive – \_list of affected entities (i.e. public interest trusts and entities maintained by them) under this <u>link</u>.







### 4.2.4 Eligible costs

#### Actual costs

Only actual cost incurred in connection with the project implementation is eligible. To be eligible the actual cost:

- must be actually incurred by the beneficiary;
- must be incurred in the project period set out in the Grant Agreement;
- must be declared under one of the budget categories listed below;
- must be incurred in connection with the action as described in the proposal and the Annex of the Grant Agreement;
- must be identifiable and verifiable, in particular recorded in the beneficiary's accounts in accordance with the accounting standards applicable in the country where the beneficiary is established and with the beneficiary's usual cost accounting practices;
- must comply with the applicable national law on taxes, labour and social security.
- must be reasonable, justified and must comply with the principle of sound financial management, in particular regarding economy and efficiency.

Eligible cost categories:

- Personnel costs
- Subcontracting costs
- Travel and subsistence (on the basis of the costs actually incurred and in line with the beneficiary's usual practices on travel)
- Other goods, works and services

### 4.3 Specific eligibility conditions

If an EIT Health Partner is affected by Council Implementing Decision (EU) 2022/2506 but can secure funding from a third party for its services tendered in this call, it is eligible to apply. The financing promise provided by a third party must be attached to the application.

#### 4.4 Exclusion

Based on the Council Implementing Decision (EU) 2022/2506 on measures for the protection of the Union budget against breaches of the principles of the rule of law in Hungary, effective as of 16th December 2022, no legal commitments shall be entered into with any public interest trust established on the basis of the Hungarian Act IX of 2021 or any entity maintained by such a public interest trust. You can find an indicative – \_non-exhaustive – \_list of affected entities (i.e. public interest trusts and entities maintained by them) under this link.

If an entity falls into in one of the exclusion situations described in Articles 136 and 141 of the EU Financial Regulation 2018/1046, they will be excluded from participation at any time (during the evaluation, contracting or implementation phases).<sup>2</sup> Applicants will have to confirm that they comply with the above conditions for receiving EU funding by signing a declaration of honour.

<sup>&</sup>lt;sup>2</sup> See Articles 136 and 141 EU Financial Regulation 2018/1046.



# 5 Evaluation and Selection

#### 5.1 Submission

- a) Applications must be submitted no later than 21 March 2025, 03:59 P.M. CET
- b) Applications must be submitted in English, using the forms provided inside the electronic submission system, <u>EIT Health Application platform</u>. The structure and presentation must correspond to the instructions given in the forms.
- c) Participants need to upload all other documents onto <u>EIT Health Application platform</u> when submitting the proposal. It is important to ensure that these documents are fully signed before uploading them onto the platform.
- d) Incomplete submissions, late submissions, or submissions via other routes (e.g., email) will not be accepted.

Mandatory annexes and supporting documents:

- Service Plan (Detailed description of service(s), its curriculum, methodology and organization of work, detailed introduction of your team, capacity of the team, actual cost of junior/senior staff and/or actual cost of service/innovator, justify that the costs are reasonable and comparable to market benchmark). More information on the evaluation criteria of the Service plan can be found in Annex I.
- Financing promise provided by a third party, if relevant (see chapter 4.3)

#### 5.2 Award criteria and scoring

Proposals failing to meet one or more admissible and eligibility criteria will receive an official communication from EIT Health, informing the Applicant of the outcome of the admissibility and eligibility check and explaining why the proposal failed to meet the criteria.

The admissible and eligible proposals will be evaluated and ranked against the following award criteria:

- Excellence and credibility of the applicant (30%)
  - The suitability of the applicant to provide the proposed services (including sub-services) based on their previous projects, history and experience.
  - The credibility of the applicant in that, based on their experience, they can provide the proposed services to several SPICE subgrantees from several RIS countries.
- Impact and well-defined service description (30%)
  - The credibility of the proposed service plan, including its content and structure, the applied methods, models, interdisciplinary approaches or the paths and tools leading to the achievement of the expected results.
  - The suitability and quality of the proposed service plan to assist SPICE subgrantees in reaching their full potential, in developing and marketing their innovative solution to the healthcare market.
- Quality and efficiency of the implementation and strength and commitment of the team (30%)
  - Activation of experienced staff to deliver the proposed services at reasonable actual costs comparable market benchmark
  - Capacity of the applicant and the extent to which the applicant brings together the necessary expertise.



- Strategic fit and alignment with EIT Health InnoStars' financial sustainability goals (10%)
  - The possibility of future collaboration (More information on the evaluation criteria can be found in Annex I.)

The independent evaluators will give a maximum of **100 points** in the remote evaluation. The overall score will be the average of all the evaluators' scores. The proposal needs to achieve an average score **above 70 points**.

Proposals that pass the overall thresholds will be put on a list of SPICE Implementing Partners. Other proposals will be rejected.

The European Commission is committed to promoting gender equality in innovation and technology. The EIT, as a body of the European Union and an integral part of Horizon Europe, plays a vital role in supporting the EU's objectives of creating sustainable economic growth and jobs by enabling entrepreneurs and innovators to turn their best ideas into products and services for Europe. EIT Health shares the EIT KIC gender diversity value statement through supporting well-being at work, compliance with domestic and EU regulations, attracting and retaining talents, economic benefits, excellence and quality, effectiveness, and efficiency of innovations and technology and as leverage for organisational change. Consequently, the gender requirements in Horizon Europe are of significant importance for all EIT Health-supported and funded activities.

### 5.3 Procedure

The call is subject to a single-stage submission and two-step evaluation procedure.

Proposals will be checked for formal requirements (admissibility and eligibility) and then evaluated (for each service separately) by an evaluation committee composed of 3 independent external experts (quality evaluation). Proposals that pass the overall thresholds are added to the long list of SPICE Implementing Partners. The SPICE subgrantees can choose a SPICE Implementing Partner based on their needs. The SPICE Implementing Partners selected by subgrantees, their service activities and their budgets will be funded by the '230101 RIS Engage Local Players' Project Grant Agreement (PGA).

Following the evaluation, all applicants will be notified of the evaluation result via email within 10 days of the final evaluation decision.

If any selected applicants cancel their participation, the next applicants with evaluation scores closest to the selection threshold will be invited to the program.

### 5.4 Grounds for appeal and appeal procedure

If an applicant disagrees with the selection decision, they may appeal the process for the selection of their own proposal(s) within 21 calendar days of receiving the result notification (<u>Appeals procedure -</u> <u>EIT Health</u>).

The only grounds for appeal are:

- Process errors;
- Technical problems beyond applicants' control (e.g., the technical failure of the electronic submission system);





- Human/technical errors made by EIT Health InnoStars staff.
- If you consider that you have been adversely affected by a particular decision not following EIT Health's Code of Conduct.

What does not constitute grounds for appeal:

 Scores awarded in the course of the proposal evaluation process (unless if these go against our Code of Conduct)

#### **Appeal process:**

- Applicants should send their appeals in writing to <u>appeals@eithealth.eu</u> as soon as they identify an error, but no later than 21 days after the error occurred.
- EIT Health assesses the claim and deliver a first response.
- If there are grounds for appeal, EIT Health will attempt to remedy the consequences (e.g. if a technical error of EIT Health prevented the submission of a proposal or application, a late submission may still be accepted as eligible).
- The Head of Compliance, and where applicable, Supervisory Board is notified about the matter if:
  - the applicant does not accept a rejection of the appeal, or
  - there are grounds for appeal, but the problem cannot be remedied any more without disrupting the process.

#### 5.5 Legal and financial set-up of the Grant Agreements

Proposals selected under this call are added to the long list of SPICE Implementing Partners, from which SPICE beneficiaries can choose one based on their needs. The SPICE Implementing Partners selected by subgrantees must join the 230101 RIS Engage Local Players Project Grant Agreement (PGA) (unless they are already implementing partners of the same PGA) and include the service activities and related budgets in the Business plan.

No activity funding will be released prior to execution of the grant agreement.

Legal document to be executed:

- a) **Project Grant Agreement (PGA)** which is the basis to govern the relationship between the EIT Health and the consortium in one specific activity as well as the relationship amongst the parties in this activity.
- b) **Financial Support Agreement (FSA)** which outlines the conditions for receiving financial support from EIT Health.
- c) **Internal Agreement** laying down the general terms and conditions under which the KIC EIT Health must operate as an institutionalized European partnership.

The standstill period for accepting the inclusion into the PGA is 15 days.

## 6 Confidentiality and conflict of interest

All proposals submitted through the application platform are accessible only to EIT Health InnoStars and EIT Health Central Office staff members for the processing of the application.



During the selection process, proposals are shared with assigned external evaluators, who are contractually bound to confidentiality. Additionally, EIT Health may give access to documentation to external advisors to support the assessment. Furthermore, EIT Health may give access to the submitted data to sub-contractors who are tasked with maintaining the application and project monitoring platform. All such third parties are also bound by confidentiality provisions.

To comply with the obligations under EIT agreements, EIT Health InnoStars may provide access to data to EIT Health and EIT staff, as well as selected external experts for reporting, checks, reviews, and auditing reasons.

EIT Health staff are bound by the <u>policy on conflicts of interest</u>. Applicants and potential beneficiaries of the EIT grant in selected activities must avoid any conflict of interest and comply with the principles of transparency, non-discrimination, and sound financial management.

## 7 Intellectual Property Rights rules

EIT Health and InnoStars do not obtain ownership of the results produced under the action. EIT Health and InnoStars and the Recipient may enter into additional arrangements regarding the use of the Results.

'Results' means any tangible or intangible effect of the action, such as data, know-how or information, whatever its form or nature, whether or not it can be protected, as well as any rights attached to it, including intellectual property rights.

EIT Health and InnoStars has the right to use non-sensitive information relating to the action and materials and documents received from the beneficiaries (notably summaries for publication, deliverables, as well as any other material, such as pictures or audio-visual material, in paper or electronic form) for policy, information, communication, dissemination and publicity purposes — during the action or afterwards.).

The recipients of funding shall comply with the IPR rules under the MGA (Article 16, see page 48). For more information, please see Article 16 of the Horizon Europe Model Grant Agreement<sup>3</sup>.

## 8 Communication and dissemination

Communication activities of the beneficiaries related to the action (including media relations, conferences, seminars, information material, such as brochures, leaflets, posters, presentations, etc., in electronic form, via traditional or social media, etc.) must acknowledge EU support and display the European flag (emblem) and funding statement ("EIT Health is supported by the European Institute of Innovation and Technology (EIT), a body of the European Union")

The emblem must remain distinct and separate and cannot be modified by adding other visual marks, brands or text. Apart from the emblem, no other visual identity or logo may be used to highlight the EU support.

<sup>&</sup>lt;sup>3</sup> https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/agr-contr/generalmga\_horizon-euratom\_en.pdf





When displayed in association with other logos (e.g. of beneficiaries or sponsors), the emblem must be displayed at least as prominently and visibly as the other logos.

## 9 Right to ex-post monitoring

The granting authority may — during the action or afterwards — check the proper implementation of the action and compliance with the obligations under the Agreement, including assessing costs and contributions, deliverables, and reports.

If needed, the granting authority may be assisted by independent, outside experts. If it uses outside experts, the beneficiary concerned will be informed and have the right to object on grounds of commercial confidentiality or conflict of interest. The beneficiary concerned must cooperate diligently and provide — within the deadline requested — any information and data in addition to deliverables and reports already submitted (including information on the use of resources). The granting authority may request beneficiaries to provide such information to it directly.





# ANNEX 1

FIELDS TO FILL IN		
First Name		
Last N	Name	
Email		
Gend	er	
Phon	e Number	
Coun	try of Residence	
Funct	tion	
Linke	dIn ( <i>if applicable, please include a valid URL</i> )	
Orgar	nization Name	
Please	e select the services you are applying for:	
-	gulatory Support	
	chnology and Innovation support ta Privacy	
	nical Validation	
	ality Assurance	
6. Bus	siness Strategy and Improvement	
	ancial Modelling	
	mmercialization Support	
	nding and Investment	
10. 10	larket scale-up and expansion	
#	EVALUATION QUESTIONS	
1	Describe your experience in the service you apply for. (Eligibility: at least 5 years of experience in the service(s) you are applying to provide, and at least 3 years of experience in each sub-service that belongs to the given service)	
2	Describe your experience in providing services to SMEs in RIS countries (Please check the current list of RIS countries here: LINK: https://eit.europa.eu/activities/eit-regional-innovation-scheme-ris-closing-innovation-divide-europe). Please list all RIS countries, where you have experience.	
3	Please demonstrate your commitment/support for the economic development of the RIS region. (e.g. projects in which you participated/managed, where the beneficiaries are/were from the RIS region)	
4	Please describe the methodology of implementation and organization of work of the service you are willing to provide.	
5	What challenges would hinder your services and how will you overcome them?	
6	Please describe the curriculum for the service you are willing to provide.	
7	Please introduce your team (team members, team Structure, Unique Team Qualifications). Briefly describe your team members' functions and provide detailed information on the staff assigned to performing the services.	
7 8	describe your team members' functions and provide detailed information on the staff assigned to	







10 Why do you want to participate in the SPICE program as an Implementing Partner? What kind of longterm commercial agreement can you imagine with InnoStars, where the developed services can be resold?

#### ACKNOWLEDGMENTS & CONSENTS

To the best of your knowledge, do you foresee any potential Conflict of Interest? If so, please describe.

Please confirm that you understand that the same legal entity cannot be a SPICE implementing partner and a SPICE subgrantee at the same time. If you have applied and been selected for both SPICE calls, you will need to decide whether to continue as a SPICE subgrantee or as a SPICE implementing partner.

Please confirm that you understand that if you are selected during this selection process, it does not constitute an automatic service order or funding.

I confirm that this submission is final. All answers and documents (if required) are filled out completely and/or have been submitted within this form. Only two submissions per organisation will be accepted. Emails or additional entries will not be considered in an evaluation. We reserve the right to exclude you from the evaluation process entirely if this is not upheld.

We have reviewed the privacy policy of EIT Health. We agree with its terms and to share our data for the purpose of the project.

## ANNEX 2

#	EVALUATION CRITERIA	MAX	
QUESTION		SCORE	
1	Excellence and credibility of the applicant (30%)	10	
2	Excellence and credibility of the applicant (30%)	10	
3	Excellence and credibility of the applicant (30%)	10	
4	Impact and well-defined service description (30%)	10	
5	Impact and well-defined service description (30%)	10	
6	Impact and well-defined service description (30%)	10	
7	Quality and efficiency of the implementation and strength and commitment	10	
	of the team (30%)		
8	Quality and efficiency of the implementation and strength and commitment	10	
	of the team (30%)		
9	Quality and efficiency of the implementation and strength and commitment	10	
	of the team (30%)	10	
10	Strategic fit and alignment with EIT Health InnoStars' financial sustainability	10	
	goals (10%)	10	

